Julie Schallhorn, MD
Ophthalmology · Los Angeles, CANPI 1700014321
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $104,310 of the $155,453 with a category attached, or 67.1%. Carl Zeiss Meditec, Inc. accounts for 61.7% of it on its own, with 20 other manufacturers making up the rest. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 175 payments — averaging $888.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$96K
- Johnson & Johnson Surgical Vision, Inc.$38K
- Vanda Pharmaceuticals Inc.$5K
- Carl Zeiss Meditec USA, Inc.$3K
- Tarsus Pharmaceuticals, Inc.$3K
- Glaukos Corporation$2K
- plus $8K from 15 others
Across 5 payments — averaging $6827.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Oyster Point Pharma, Inc.$34K
What the payments were for
- Consulting fees$104,31067%
- Speaking & faculty fees$22,73215%
- Travel & lodging$17,37111%
- Food & beverage$8,9256%
- Gifts$170%
- Other$2,0971%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 77 | $95,857 |
| Johnson & Johnson Surgical Vision, Inc. | 38 | $38,349 |
| Vanda Pharmaceuticals Inc. | 4 | $5,030 |
| Carl Zeiss Meditec USA, Inc. | 17 | $3,339 |
| Tarsus Pharmaceuticals, Inc. | 2 | $2,588 |
| Glaukos Corporation | 7 | $2,408 |
| Novartis | 1 | $2,100 |
| Bausch & Lomb Americas Inc. | 3 | $1,388 |
| Oculus, Inc. | 1 | $1,000 |
| Sight Sciences, Inc. | 1 | $1,000 |
| AbbVie | 4 | $853 |
| Beaver-visitec International, Inc. | 2 | $270 |
| Alcon | 5 | $257 |
| Alcon Research LLC | 2 | $235 |
| Rxsight Inc | 4 | $219 |
| Oyster Point Pharma, Inc. | 2 | $202 |
| Genentech, Inc. | 1 | $149 |
| Lensar, Inc. | 1 | $148 |
| W. L. Gore & Associates, Inc. | 1 | $28 |
| Dompe US, Inc. | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IOLMaster 700$42,409
- Humphrey HFA$27,498
- ARTEVO 800$27,327
- VisuMax$26,674
- Tecnis IOL$25,141
- CIRRUS HD-OCT$24,772
- Compact Intuitiv$23,800
- Healon Duet Pro$23,800
- FORUM$22,623
- FORUM Glaucoma Workplace$20,800
- VERACITY SURGICAL$17,139
- CALLISTO eye$9,363
- IOLMaster$7,700
- Retina Workplace$7,150
- Cataract Suite$6,463
- MEL 90$3,773
- QUATERA 700$3,611
- XIIDRA$3,350
- KXL System$2,100
- LUMERA 700$1,787
How this compares
$155,453 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 172 | $8,984 |
| MoxifloxacinMoxifloxacin Hcl | 153 | $6,389 |
| Fluorometholone | 47 | $5,421 |
| TafluprostTafluprost/Pf | 12 | $1,823 |
| Brimonidine Tartrate | 21 | $1,784 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 13 | $1,004 |
| Difluprednate | 13 | $917 |
| ValacyclovirValacyclovir Hcl | 12 | $837 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 74 | $578 |
| Ketorolac Tromethamine | 26 | $400 |
| Latanoprost | 25 | $386 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 21 | $264 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 13 | $197 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Los Angeles
- Andrew MoshfeghiLos Angeles$895K
- Barry SeibelLos Angeles$835K
- Nicole FramLos Angeles$551K
- Neda ShamieLos Angeles$547K
- David BoyerLos Angeles$406K
- David HamiltonLos Angeles$359K
- Arjan HuraLos Angeles$306K
- Firas RahhalLos Angeles$264K
- Kouros NourimahdaviLos Angeles$258K
- Daniel RootmanLos Angeles$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.